Mersana Therapeutics Obtains $35,000,000 Series B Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ae3572c9-c435-4407-89ee-3612be2ea6c0
Date
3/2/2015
Company Name
Mersana Therapeutics
Mailing Address
840 Memorial Drive Cambridge, MA 02139 USA
Company Description
Mersana Therapeutics, Inc. (formerly Nanopharma Corp.) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs.
Website
http://www.mersana.com
Transaction Type
Venture Equity
Transaction Amount
$35,000,000
Transaction Round
Series B
Proceeds Purposes
The proceeds will fund the advancement of Mersana’s pipeline of products based on its novel Fleximer antibody-drug conjugate (ADC) platform with its first investigational new drug (IND) filing anticipated later this year.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor